Journal
NATURE REVIEWS CANCER
Volume 7, Issue 3, Pages 192-201Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2073
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA101318-04, R01 CA101318] Funding Source: Medline
- NIBIB NIH HHS [U54 EB005149, U54 EB005149-030013] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA101318] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [U54EB005149] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The mechanism(s) for chemotherapy-induced cognitive changes are largely unknown; however, several candidate mechanisms have been identified. We suggest that shared genetic risk factors for the development of cancer and cognitive problems, including low-efficiency efflux pumps, deficits in DNA-repair mechanisms and/or a deregulated immune response, coupled with the effect of chemotherapy on these systems, might contribute to cognitive decline in patients after chemotherapy. Furthermore, the genetically modulated reduction of capacity for neural repair and neurotransmitter activity, as well as reduced antioxidant capacity associated with treatment-induced reduction in oestrogen and testosterone levels, might interact with these mechanisms and/or have independent effects on cognitive function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available